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GINA, What Could You Do for Me One Day?:  
The Potential of the Genetic Information 
Nondiscrimination Act to Protect the American Public 
Lauren J. Sismondo* 
INTRODUCTION 
This Note addresses genetic privacy and proposed federal 
legislation that purports to afford all citizens the right to genetic 
privacy as applied to employment and insurance. Scholars debate 
whether genetic privacy and genetic discrimination are concerns that 
should be addressed by federal legislation. Many argue that the best 
way to further development in genetic research and to secure citizen 
cooperation in clinical genetic research trials is to legislate, thereby 
alleviating the public’s concern about the possibility of genetic 
discrimination.  
Part I of this Note discusses the theory of genetic exceptionalism, 
the theory that genetic information is somehow different from other 
medical data and therefore deserves a higher degree of protection. 
This section explores the idea of discrimination based on genetics, 
demonstrating that Americans fear discrimination based on genetic 
make-up, something over which they have no control. This fear of 
genetic discrimination pervades the employment and insurance 
realms, on which most people are deeply dependent. 
Part II analyzes existing federal legislation as applied to genetic 
information in the context of maintaining privacy and preventing 
discrimination. Part III examines the Genetic Information 
Nondiscrimination Act of 2005 (GINA),1 currently pending in the 
 
 * J.D. (2006), Washington University School of Law; B.S. in Biological Sciences 
(2003), Carnegie Mellon University. 
 1. Genetic Information Nondiscrimination Act of 2005, S. 306, 109th Cong. (2005). 
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United States House of Representatives, for its potential to prevent 
genetic discrimination in employment and insurance.2  
Part IV addresses a 2001 case between the Equal Employment 
Opportunity Commission (EEOC) and Burlington Northern & Santa 
Fe Railway (BNSF).3 This case was the first lawsuit ever filed 
alleging genetic discrimination in employment.4 However, because 
the case settled out of court and did not go to trial, there is still no 
direct evidence as to how a court would rule on genetic 
discrimination.  
Part V explores several questions left unanswered because of the 
lack of judicial resolution of the BNSF case. If a similar case of 
genetic discrimination were to occur, would GINA, the proposed 
federal legislation, be of any value? Would a defendant such as 
BNSF be able to allege that its testing is different and not used in a 
discriminatory manner? Finally, Part VI answers the questions of 
how protective GINA would really be and whether it should be 
enacted by Congress. 
I. GENETIC INFORMATION, GENETIC TESTING, AND THE FEAR OF 
GENETIC DISCRIMINATION 
Genetic information is seen as a unique entity that requires special 
attention. This view is based on the theory of genetic exceptionalism, 
which distinguishes genetic information from other types of medical 
information as more sensitive and subject to misuse.5 Because 
 
 2. The majority of this Note was written while the 2003 version of GINA was pending in 
the House of Representatives. See Genetic Information Nondiscrimination Act of 2003, S. 
1053, 108th Cong. (2003). The Senate Report corresponding to the 2003 version of the bill and 
other sources relating to it are used extensively throughout this Note for reference and support. 
Because the 2003 and 2005 versions of GINA are substantially the same, these sources are both 
informative and useful in analyzing both versions of the bill. 
 3. EEOC v. Burlington N. Santa Fe Ry. Co., Civ. No. 01-4013 MWB (N.D. Iowa Apr. 
18, 2001) (granting preliminary settlement agreement).  
 4. Id. 
 5. See ASHLEY BISER, COUNCIL FOR RESPONSIBLE GENETICS, GENETIC INFORMATION 
AND EMPLOYMENT: A REPORT ON LAW IN THE UNITED STATES (2004), http://www. 
genelaw.info/reports/employment.pdf. The following factors, while not unique to genetic 
information, combine to make genetic information more vulnerable: 
First, there is a long history of the abuse of hereditary information in the eugenics 
movements. Second, genetic information is considered uniquely intimate in that it 
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genetic tests, non-genetic medical tests, and family medical histories 
can all provide some type of genetic information, it is difficult to 
obtain a precise definition of genetic information.6 One useful 
summary of the characteristics of genetic information is as follows: 
Genetic information relates to families and not just individuals; 
genetic information can offer a degree of certainty in 
determining which of those persons is likely to be affected by 
genetic disease; genetic information can provide a measure of 
predictability in the assessment of likelihood of ill health in 
particular individuals from an affected group; genetic 
information can reveal secrets about future ill health, even in 
those who are currently well; genetic information can help to 
determine future risks in future persons, i.e. one’s progeny.7 
Presently, genetic tests cover four main areas.8 First, genetic tests 
can identify a disease in individuals who exhibit few clinical 
symptoms.9 Second, testing can identify individuals who are 
presymptomatic, but will be affected with a late-onset disease.10 
 
provides predictive information about an individual’s future health status. Third . . . 
genetic information provides data about not only the individual in question, but their 
family members as well. 
Id. at 4. For a discussion opposed to the theory of genetic exceptionalism, see Sonia M. Suter, 
The Allure and Peril of Genetics Exceptionalism: Do We Need Special Genetics Legislation?, 
79 WASH. U. L.Q. 669 (2001).  
 6. See Michael S. Yesley, Protecting Genetic Difference, 13 BERKELEY TECH. L.J. 653, 
659 (1998). For example, “most clinical tests detect abnormal concentrations of biochemical 
entities, which can provide information about the genes that code for those entities, as well as 
the functioning of various organs. Thus, practically every clinical test may be considered a test 
for gene products.” Id. at 661 (footnote omitted). Therefore, the determination of what is a 
genetic test “may depend on the context or purpose of the test: for example, whether cholesterol 
is tested in an individual with a family history of hypercholesterolemia or as part of a routine 
physical.” Id.  
 7. GRAEME LAURIE, GENETIC PRIVACY: A CHALLENGE TO MEDICO-LEGAL NORMS 104 
(1st ed. 2002). “However, other examples of information which functions in one or more of 
these fashions can also be derived from non-genetic data, or at least from data that have not 
traditionally been considered to be genetic.” Id.  
 8. For more information on the scope and usefulness of genetic testing in general, see id. 
at 86–113.  
 9. See BISER, supra note 5, at 2. 
 10. Id. Huntington’s disease is one type of late-onset disorder. Id. For more information 
on Huntington’s disease, see Huntington’s Disease Society of America, http://www.hdsa.org 
(last visited Aug. 16, 2006). 
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Third, genetic tests can indicate predisposition to a disease by 
locating associated gene sequences.11 Finally, genetic tests can be 
used to identify individuals more susceptible to certain environmental 
hazards.12  
While genetic testing seems promising to some, others have 
reservations about the widespread use of genetic testing and the 
amount of information that can be obtained. As one critic states, 
“[f]ear that genetic information will be misused to harm individuals 
. . . casts a shadow over [the] glowing portrait of the future of 
genomic medicine.”13 Part of the reason for this fear is the number of 
parties interested in genetic information—genetic information is 
important not only to the individual to whom it pertains, but also to 
relatives, employers, insurers, researchers, and the government.14 
Scholars debate whether the fear of genetic discrimination is 
based in reality.15 Widespread genetic testing in the workplace has 
 
 11. See BISER, supra note 5, at 2. This type of genetic test is more controversial, due to 
the unreliability of the test. These tests are available for many diseases, such as cystic fibrosis, 
Alzheimer’s disease, breast cancer, colon cancer, and Parkinson’s disease. See NAT’L COUNCIL 
ON DISABILITY, POSITION PAPER ON GENETIC DISCRIMINATION LEGISLATION 2 (2002), 
http://www.ncd.gov/newsroom/publications/2002/pdf/geneticdiscrimination_positionpaper.pdf 
[hereinafter NCD POSITION PAPER]. A specific example is the BRCA1 or 2 gene associated 
with an increased risk of breast cancer. See BISER, supra note 5, at 2. For more information 
about the genes associated with an increased risk of breast cancer, see National Cancer Institute, 
Genetic Testing for BRCA1 and BRCA2, http://www.cancer.gov/cancertopics/factsheet/Risk/ 
BRCA (last visited Aug. 16, 2006). 
 12. See BISER, supra note 5, at 2. “[I]t is assumed that genetic information may at some 
point in the future be able to both provide employers with predictive health data and warn 
employers about individual employees’ susceptibility to environmental hazards.” Id.  
 13. Patricia A. Roche, The Genetic Revolution at Work: Legislative Efforts to Protect 
Employees, 28 AM. J.L. & MED. 271, 271 (2002). “A job action based on a genetic 
predisposition is rooted in an employer’s fears, myths, and stereotypes, rather than in an 
employee’s ability to do the job, and therefore constitutes unlawful discrimination.” Paul 
Steven Miller, Genetic Discrimination in the Workplace, 26 J.L. MED. & ETHICS 189, 194 
(1998).  
 14. See LAURIE, supra note 7, at 113. The level of interest varies, but is usually based on 
the perception that the genetic information will provide a personal, economic, societal, or 
paternalistic benefit. Id. at 114. 
 15. See William Nowlan, A Rational View of Insurance and Genetic Discrimination, 297 
SCIENCE 195 (2002). Nowlan believes that it is an “erroneous belief that the threat of genetic 
discrimination by health insurers represents a clear and present danger.” Id. He also thinks it “is 
increasingly likely that the power of genetic testing to predict mortality in otherwise healthy 
adults will never be compelling enough to justify the expense of testing or the inevitable public 
furor.” Id. at 196 (footnotes omitted). But see Karen H. Rothenberg & Sharon F. Terry, Before 
It’s Too Late—Addressing Fear of Genetic Information, 297 SCIENCE 196 (2002). “Regardless 
https://openscholarship.wustl.edu/law_journal_law_policy/vol21/iss1/18
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not yet occurred, therefore limiting possible instances of 
discrimination.16 Several factors contribute to this result. First, “[f]ew 
genetic sequences have been identified which could offer predictive 
information with the sort of accuracy needed for widespread genetic 
screening.”17 The cost and questionable reliability of genetic tests 
also limit their use by employers.18 In addition, it is doubtful that 
widespread genetic testing would be cost-effective for employers 
because of the short-term nature of many employment contracts.19 
Nonetheless, employers’ interest in the genetic information of their 
employees is expected to increase in the future.20 
Regardless of whether the fear of genetic discrimination is 
justified,21 numerous studies show that the public is concerned.22 
 
of whether fear of genetic discrimination is based on perception or reality, we must find a way 
to ensure public confidence in genetics research and the use of genetic information.” Id. at 197.  
 16. See BISER, supra note 5, at 2. However, “[t]he concern is that employers could use 
[genetic] data to weed out those most likely to incur large medical expenses—either through 
increased health care costs or workers’ compensation claims.” Id. 
 17. Id.  
 18. Id.  
 19. Id. “In a 2001 survey of large U.S. firms, only 1.3% of firms used a genetic test to 
identify individuals with sickle-cell anemia, and less than 1% of firms tested either employees 
or new-hires for the gene associated with Huntington’s Disease.” Id. (footnote omitted). 
 20. Id. at 3. Biser described the cost-benefit calculation: 
Whether predictive genetic information will eventually be of use to employers in 
assessing the future health characteristics of workers has yet to be determined; as the 
cost of testing decreases and the information to be gleaned from such tests becomes 
more accurate, it is predicted that the incentive for employers to gain access to genetic 
information will increase. 
Id. at 1.  
 21. When asked in an interview about public fears of genetic discrimination, Francis 
Collins, M.D., Ph.D., and the director of the National Human Genome Research Institute, 
observed: “You could say they are overestimating the risk, but these are people who are given 
the facts and this is the decision they make. Remember, genetic test results follow you for life—
they aren’t going to change.” Joel B. Finkelstein, Protecting Genetic Privacy, AM. MED. NEWS, 
Apr. 5, 2004, at 6.  
 22. See Rothenberg & Terry, supra note 15, at 196–97. “[W]orkers clearly fear that 
employers will use genetic information to lower their insurance and sick leave costs by weeding 
out individuals who have traits linked to inherited medical conditions.” Miller, supra note 13, at 
189. One study, conducted at the National Institutes of Health, investigated the attitudes and 
intentions of patients about undergoing genetic testing for the most common form of hereditary 
colon cancer, hereditary nonpolyposis colorectal cancer. See Donald W. Hadley et al., Genetic 
Counseling and Testing in Families with Hereditary Nonpolyposis Colorectal Cancer, 163 
ARCHIVES INTERNAL MED. 573 (2003). Thirty-nine percent of eligible participants chose not to 
undergo testing because of the potential effect on their health insurance coverage. Id. 
Washington University Open Scholarship
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Because most ordinary citizens do not understand the complexities of 
genetics, “[p]ublic education is needed so patients have a better 
understanding of both the power and limits of genetic testing.”23 Fear 
of discrimination leaves many individuals wary of genetic testing, 
which hurts not only themselves,24 but the scientific community as 
well.25 For example, many institutional review boards, in response to 
public concerns, have added language to their informed consent 
documents that warns of the risk of genetic discrimination resulting 
from participation in genetic research.26 However, scientists and 
 
 23. Finkelstein, supra note 21, at 6 (quoting Dr. Nancy L. Fisher, geneticist and clinical 
associate professor at the University of Washington). In addition, because most diseases are 
very complex, genetic information alone is insufficient for understanding the disease in its 
entirety. “[L]egislation will have to recognize these nuances [of diseases] in order to provide a 
balance between an employer’s interest in safety and an individual’s interest in protecting his or 
her genetic information.” BISER, supra note 5, at 5. 
 24. “These fears eliminate people’s opportunities to learn that they are not at increased 
risk for the genetic disorder in the family or to make lifestyle changes to reduce risks.” NCD 
POSITION PAPER, supra note 11, at 5. 
 25. See Miller, supra note 13, at 190. “[M]edical researchers have voiced concerns 
because individuals are refusing to participate in long-term medical studies to assess their risk 
of developing genetically linked diseases . . . because these individuals believe that involvement 
in such studies would be a red flag on their medical records that could subject them to genetic 
discrimination.” Id. Without protection from genetic discrimination, “individuals who do agree 
to participate [in genetic research] will represent a self-selected group that could skew research 
results, producing a negative impact on all of us who look to genetics to help find better ways of 
diagnosing, treating, and preventing disease.” Francis Collins & James D. Watson, Editorial, 
Genetic Discrimination: Time to Act, 302 SCIENCE 745 (2003).  
 26. See Aaron Hamvas et al., Informed Consent for Genetic Research, 158 ARCHIVES 
PEDIATRIC ADOLESCENT MED. 551, 552 (2004). Washington University is one institution where 
this has occurred. Id. During a study on infants to determine the connection between a genetic 
variation in the surfactant protein B gene and a higher risk of respiratory distress syndrome, 
researchers also studied the reasons why parents refused to consent to their infant’s 
participation in the study. Id. at 551–52. The specific language Washington University used on 
the consent form was as follows:  
(1) An insurance company might consider participation in genetic research in a family 
study an indication that there is a family history of a genetic condition; (2) If your 
baby’s participation in a genetic study becomes known outside of the research (for 
example, if your baby’s participation were noted in her/his medical record), your baby 
(and family members) may be unable to obtain health, life, or disability insurance; and 
(3) You and/or your baby might also be refused employment or be terminated from 
your current employment. 
Id. at 553 (internal quotations omitted). The study showed that ninety-seven percent of 
nonconsenting families feared language on the consent form that indicated the possibility of 
genetic discrimination. Id.  
https://openscholarship.wustl.edu/law_journal_law_policy/vol21/iss1/18
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doctors predict that genetic information will soon be an inevitable 
part of most medical records and will be of great importance in 
maintaining good health; fear of genetic discrimination is thus a 
barrier to progress.27 
The best way to address this concern is with federal legislation 
aimed at preventing genetic discrimination.28 Precluding any 
possibility of genetic discrimination would ensure fairness and 
equality for everyone.29 As one author notes, “[i]f you have a 
circumstance where somebody can lose [the right to health care] 
 
 This study suggests that the possibility of losing employment and insurance defines the 
social context in which families determine whether to consent to a genetic study, even in the 
absence of any legal precedent or evidence showing that genetic discrimination is a reality. Id. 
at 554. It also concluded that “institutionally required alarmist statements tend to perpetuate 
misconceptions about the current state of genetic technology rather than promote deliberate 
discussion with families or patients.” Id. The researchers suggested that “information about 
federally and institutionally mandated protections for confidentiality of participants in genetic 
research should be included in the informed consent document to balance the description of 
hypothetical risks and more accurately inform subjects.” Id. The uniformity of responses 
suggests that the language required by the institutional review board “scar[ed] rather than 
inform[ed] families” of risks, especially since there are no known cases of genetic 
discrimination arising from participation in a genetic study. Id. The language of the informed 
consent document for participation in genetic research at Washington University was modified, 
as of March 15, 2004, to read as follows:  
You and family members may be unable to get health, life, or disability insurance if 
the information in this study becomes known. Rarely, you may have problems getting 
or keeping a job. This could happen if you talk to your doctor about your participation 
without asking that the information be kept out of your medical record. Having genetic 
information in your medical record may allow insurance providers to get this 
information. 
Id. at 554–55.  
 27. See Philip R. Reilly, Genetic Discrimination, in GENETIC TESTING AND THE USE OF 
INFORMATION 106, 129 (Clarisa Long ed., 1999). One prominent scientist noted that 
personalized medicine based on genetics is realistic: “Doctors will also begin tailoring 
prescribing practices to each patient’s unique genetic profile, choosing medications that are 
most likely to produce a positive response.” Francis S. Collins, Personalized Medicine: A New 
Approach to Staying Well, BOSTON GLOBE, July 17, 2005, at E12. 
 28. Some have argued that protecting privacy and preventing discrimination are not the 
best ways to deal with genetic information, and that a property rights approach may be a better 
option. For a discussion of this argument, see Sonia M. Suter, Disentangling Privacy from 
Property: Toward a Deeper Understanding of Genetic Privacy, 72 GEO. WASH. L. REV. 737 
(2004). 
 29. For example, the National Council on Disability supports federal genetic 
discrimination legislation, noting that “due to narrow judicial interpretations of ADA . . . these 
same interpretations also create the need for legislation to restore protections for individuals 
who have actually developed health conditions.” NCD POSITION PAPER, supra note 11, at 2. 
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based on something they have no control over—their DNA 
sequence—then you have a fundamentally unjust system.”30 
II. EXISTING FEDERAL LAWS THAT MAY PROTECT AGAINST GENETIC 
DISCRIMINATION 
Currently, no federal legislation specifically protects against 
genetic discrimination in individual insurance coverage or in the 
workplace.31 Most legislation has occurred at the state level, where a 
complex assortment of genetic discrimination laws exists.32 However, 
there are several federal anti-discrimination laws, including the 
Americans with Disabilities Act of 1990 (ADA),33 the Health 
Insurance Portability and Accountability Act of 1996 (HIPAA),34 and 
Title VII of the Civil Rights Act of 1964 (Title VII),35 whose 
provisions can be interpreted to prohibit genetic discrimination.36 In 
 
 30. Finkelstein, supra note 21, at 6 (quoting Dr. Frances Collins). Dr. Collins also asserted 
that “it will be much easier to nip this in the bud before it has become widespread than to wait 
until there is already a sort of standard practice in the insurance industry or the human resources 
office to find out information about people’s genetics.” Id. But see Yesley, supra note 6, at 663. 
Yesley observes that “[l]aws barring genetic discrimination in health insurance do not respond 
to a substantial problem but to a perceived threat of loss of insurance that might hinder genetic 
researchers’ search for human subjects.” Id. Yesley points out that while legislation aimed at 
removing the fear of insurance loss “may seem a reasonable step,” the costs of such legislation 
must also be considered. Id. The “piecemeal approach of barring genetic discrimination” in 
health insurance may help some, but “it also removes a compelling argument for the ultimate 
goal of universal health coverage.” Id.  
 31. See Miller, supra note 13, at 190 (“No current federal statute explicitly addresses 
genetic discrimination by employers.”). 
 32. State laws have been described as “a patchwork of provisions which are incomplete, 
even inconsistent, and which fail to follow a coherent vision for genetic screening, counseling, 
treatment and prevention of discrimination.” NCD POSITION PAPER, supra note 11, at 9–10 
(quoting Larry Gostin, Genetic Discrimination: The Use of Genetically Based Diagnostic and 
Prognostic Tests by Employers and Insurers, 17 AM. J.L. & MED. 109, 142 (1991)). For more 
detailed information regarding state genetic legislation, see BISER, supra note 5, at 12; William 
F. Mullholland II & Ami S. Jaeger, Genetic Privacy and Discrimination: A Survey of State 
Legislation, 39 JURIMETRICS J. 317 (1999); Human Genome Project Information, Genetics 
Legislation, http://www.ornl.gov/sci/techresources/Human_Genome/elsi/legislat.shtml (last 
visited Aug. 16, 2006) [hereinafter Genetics Legislation]. 
 33. Americans with Disabilities Act, 42 U.S.C. §§ 12111–117 (2000). 
 34. Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191, 
110 Stat. 1936 (codified in scattered sections of 26 U.S.C., 29 U.S.C. and 42 U.S.C.). 
 35. Civil Rights Act of 1964, 42 U.S.C. § 2000e (2000).  
 36. See Miller, supra note 13, at 190–91. This is “because genetic discrimination may 
have a disparate impact based on race, color, religion, sex, or national origin.” Id. at 191. 
https://openscholarship.wustl.edu/law_journal_law_policy/vol21/iss1/18
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addition, President Clinton signed an executive order that prohibits 
discrimination in employment based on genetic information; 
however, it applies only to federal employees.37 
The ADA generally protects private sector employees from 
discrimination on the basis of disability, but it uses broad language 
and does not explicitly mention genetic discrimination.38 The ADA 
defines disability in three ways: “(a) a physical or mental impairment 
that substantially limits one or more of the major life activities of 
such individual; (b) a record of such an impairment; or (c) being 
regarded as having such an impairment.”39 The Equal Employment 
Opportunity Commission (EEOC) enforces the ADA,40 and, in 1995, 
determined that the ADA “prohibits discrimination against workers 
based on their genetic make-up.”41 The EEOC guidelines are only 
persuasive authority, however, and have not yet been tested in 
court.42 
HIPAA is the only enacted federal law that directly addresses 
genetic discrimination.43 However, HIPAA only applies to 
“employer-based and commercially issued group health insurance.”44 
HIPAA “[p]rohibits group health plans from using any health status-
related factor, including genetic information, as a basis for denying or 
 
 37. Exec. Order No. 13,145, 3 C.F.R. 235 (2001), reprinted in 42 U.S.C.A. § 2000e–1b 
(West 2003). 
 38. See 42 U.S.C. § 12112(a) (2000). 
 39. Id. § 12102(2). “While one piece of EEOC guidance has suggested that those with 
presymptomatic or asymptomatic genetic abnormalities would be ‘regarded as’ having a 
disability and therefore eligible for the act’s protections, others have argued, and the EEOC 
would not foreclose, that asymptomatic genetic conditions constitute an ‘actual’ disability.” 
BISER, supra note 5, at 10. 
 40. 42 U.S.C. § 12206(c)(2)(A) (2000); see also Press Release, EEOC, EEOC Petitions 
Court to Ban Genetic Testing of Railroad Workers in First EEOC Case Challenging Genetic 
Testing Under Americans with Disabilities Act (Feb. 9, 2001), available at http://www. 
eeoc.gov/press/2-9-01-c.html [hereinafter EEOC Feb. Press Release]. The ADA also prohibits 
employers from seeking disability-related information that is unrelated to the employee’s ability 
to perform his or her job. Id.  
 41. Miller, supra note 13, at 190–91; see 2 EEOC Compl. Man. (CCH) § 902 (Mar. 14, 
1995). 
 42. See Genetics Legislation, supra note 32. “And yet, courts have not yet determined 
whether the ADA should be understood to restrict discrimination on the basis of a diagnosed, 
but asymptomatic, genetic condition or trait.” Miller, supra note 13, at 190.  
 43. See HIPAA, Pub. L. No. 104-191, 110 Stat. 1936 (codified in scattered sections of 26 
U.S.C., 29 U.S.C. and 42 U.S.C.). 
 44. See Genetics Legislation, supra note 32. 
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limiting eligibility for coverage or for charging an individual more 
for coverage.”45 However, HIPAA explicitly states that genetic 
information in the absence of a current diagnosis of illness is not a 
preexisting condition.46 This provision is problematic, and affects 
both those with late-onset diseases and those predisposed to disease.47  
Both the ADA and HIPAA fail to address family medical 
histories.48 Many employers require prospective employees to 
provide family medical histories because they are good predictors of 
the likelihood of developing disease.49 Therefore, “family medical 
history constitutes a form of genetic information that goes largely 
unregulated.”50  
Title VII of the Civil Rights Act of 1964 could support an 
argument that genetic discrimination based on a racially or ethnically 
linked genetic disease constitutes unlawful discrimination.51 
However, this protection would be available only for diseases linked 
to specific protected groups, such as sickle-cell52 or Tay-Sachs 
 
 45. See id. 
 46. See HIPAA, 110 Stat. 1936 § 701(b)(1)(B); see also BISER, supra note 5, at 8. 
“HIPAA states that a genetic condition . . . [if] it is not the basis of a clinical diagnosis, cannot 
be considered a preexisting condition for the purposes of health insurance exclusions and 
cannot be . . . the basis of a limitation or exclusion, unless such provisions are applied to all 
‘similarly situated individuals.’” Id. (quoting 42 U.S.C. §§ 300gg(b)(1), 300gg–1 (2000)). In 
addition, HIPAA “does not address the larger problem of gathering or using genetic information 
in the workplace outside the health insurance context.” Miller, supra note 13, at 192. For a 
more extensive discussion of HIPAA and genetics, see Mark A. Rothstein, The Law of Medical 
and Genetic Privacy in the Workplace, in GENETIC SECRETS: PROTECTING PRIVACY AND 
CONFIDENTIALITY IN THE GENETIC ERA 281 (Mark A. Rothstein ed., 1997).  
 47. See supra notes 9–10 and accompanying text.  
 48. See BISER, supra note 5, at 8. 
 49. See id. at 3, 8. “While few employers reported using genetic tests directly, 20% 
reported requesting family medical histories of employees or new-hires . . . [m]ore importantly, 
almost 5% of those surveyed reported using family medical histories in employment decision-
making practices.” Id. at 3. 
 50. Id. at 8.  
 51. See 42 U.S.C. § 2000e-2(a) (2000). It is an unlawful employment practice for an 
employer “to fail or refuse to hire or to discharge any individual, or otherwise to discriminate 
against any individual . . . because of such individual’s race, color, religion, sex, or national 
origin,” or “to limit, segregate, or classify his employees or applicants for employment in any 
way which would deprive or tend to deprive any individual of employment opportunities or 
otherwise adversely affect his status as an employee, because of such individual’s race, color, 
religion, sex, or national origin.” Id.  
 52. Sickle cell disease is an autosomal recessive anemia, characterized by an unstable 
hemoglobin variant (Hb S). Homozygotes generally have severe anemia, while heterozygotes 
are sickle cell trait carriers with minimal clinical problems. Sickle cell disease occurs most 
https://openscholarship.wustl.edu/law_journal_law_policy/vol21/iss1/18
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disease.53 Therefore, because most genetic diseases do not 
disproportionately affect a Title VII protected group, Title VII’s 
protection against genetic discrimination is not comprehensive.54 
President Clinton’s executive order prohibits the use of genetic 
information55 in any hiring or promotion action by all federal 
departments and agencies.56 Specifically, the order prohibits the use 
of genetic tests and information as a condition of hiring or receiving 
benefits57 or to classify employees in a way that deprives them of 
advancement opportunities.58 However, this order is underinclusive 
 
often in individuals of African descent. See STEDMAN’S MEDICAL DICTIONARY 80 (28th ed. 
2006). 
 53. Tay-Sachs disease, a lysosomal storage disease, results from hexosaminidase A 
deficiency. Within three to six months, infants begin rapid neurological deterioration, and death 
occurs within a few years. Id. Tay-Sachs is an autosomal-recessive transmission, found 
primarily in Jewish populations. Id.  
 54. See Miller, supra note 13, at 191–92. 
 55. Exec. Order No. 13,145, 3 C.F.R. 235 (2001). Protected genetic information is defined 
in subparagraph (1) as: “(A) information about an individual’s genetic tests; (B) information 
about the genetic tests of an individual’s family members; or (C) information about the 
occurrence of a disease, or medical condition or disorder in family members of the individual.” 
Id. at 236. The order further provides that “[i]nformation about an individual’s current health 
status (including information about sex, age, physical exams, and chemical, blood, or urine 
analyses) is not protected genetic information unless it is described in subparagraph (1).” Id. 
This raises concern about the correctness of the definition of genetic information. See supra 
note 6 and accompanying text. 
 56. The order provides: 
It is the policy of the Government of the United States to provide equal employment 
opportunity in Federal employment for all qualified persons and to prohibit 
discrimination against employees based on protected genetic information, or 
information about a request for or the receipt of genetic services. This policy of equal 
opportunity applies to every aspect of Federal employment. 
Exec. Order No. 13,145, 3 C.F.R. 235. 
 57. Id. at 236.  
The employing department or agency shall not discharge, fail or refuse to hire, or 
otherwise discriminate against any employee with respect to the compensation, terms, 
conditions, or privileges of employment of that employee, because of protected genetic 
information with respect to the employee, or because of information about a request 
for or the receipt of genetic services by such employee.  
Id.  
 58. Id.  
The employing department or agency shall not limit, segregate, or classify employees 
in any way that would deprive or tend to deprive any employee of employment 
opportunities or otherwise adversely affect that employee’s status, because of 
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because it only protects federal employees;59 in the private sector, 
employment discrimination based on genetics is not yet prohibited.60 
III. PENDING FEDERAL LEGISLATION: GENETIC INFORMATION 
NONDISCRIMINATION ACT OF 2005 
In October, 2003, the United States Senate passed the Genetic 
Information Nondiscrimination Act of 2003 (GINA).61 The bill is the 
first federal legislation to exclusively address the issue of genetic 
privacy.62 The bill’s unanimous passage, with a vote of 95–0, ended 
six years of legislative gridlock.63 
The House of Representatives took no action with the 2003 
version of GINA. As a result, the United States Senate, in February, 
2005, passed the Genetic Information Nondiscrimination Act of 
2005.64 The text of this bill is substantially similar to the 2003 
version. The Senate passed the 2005 version of GINA with a 
 
protected genetic information with respect to the employee or because of information 
about a request for or the receipt of genetic services by such employee. 
Id.  
 59. Id.; see also Genetics Legislation, supra note 32. 
 60. See BISER, supra note 5, at 9. “[T]he federal government has yet to enact legislation 
prohibiting private sector employment discrimination on the basis of genetic information.” Id. 
But see GINA of 2003, S. 1053, 108th cong. (2003). 
 61. GINA of 2003, S. 1053. The Senate report accompanying the bill provided: 
The purpose of this legislation is to protect individuals from discrimination in health 
insurance and employment on the basis of genetic information. Establishing these 
protections will allay concerns about the potential for discrimination and encourage 
individuals to participate in genetic research and to take advantage of genetic testing, 
new technologies, and new therapies. The legislation will provide substantive 
protections to those individuals who may suffer from actual genetic discrimination 
now and in the future. These steps are essential to fulfilling the promise of the human 
genome project.  
S. REP. NO. 108-122, at 1–2 (2003). 
 62. See Sheryl Gay Stolberg, Senate Sends to House a Bill on Safeguarding Genetic 
Privacy, N.Y. TIMES, Oct. 15, 2003, at A12. 
 63. See id. “Negotiators said the measure had been mired in disputes over details, 
including the precise definition of genetic testing. The disagreements took years to work out, 
they said, because the topics were so complex.” Id.  
 64. GINA of 2005, S. 306, 109th Cong. (2005). As noted, supra note 2, the majority of 
this Note was written while the 2003 version of the bill was pending. For that reason, sources 
referring to the 2003 version are used throughout. 
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unanimous 98-0 vote.65 This bill is still on hold in the House of 
Representatives. 
GINA, if passed by the House, will set new standards for 
safeguarding genetic privacy. GINA defines genetic information 
rather broadly as information about “an individual’s genetic tests; the 
genetic tests of family members of the individual; or the occurrence 
of a disease or disorder in family members of the individual.”66 It will 
prevent insurance companies from using genetic information in 
deciding enrollment in health plans or in underwriting.67 In addition, 
employers will be permitted to use information from genetic tests 
only to determine workplace exposures,68 but never for hiring 
purposes.69 
GINA prohibits the use of genetic information in any type of 
employment decision, rather than prohibiting only unfair 
 
 65. See Collins, supra note 27. “The president has indicated strong support, but the bill 
remains before the House of Representatives, with no hearings scheduled. Given that more than 
800 genetic tests are now available and hundreds more are on the horizon, we need this 
legislation.” Id.  
 66. GINA of 2005, S. 306 § 201(4)(A). “The inclusion of this last provision is particularly 
significant, because it protects against the use of family history information, as well as 
information gathered through DNA or RNA-based tests.” BISER, supra note 5, at 11. Genetic 
tests are further defined by the bill as “the analysis of human DNA, RNA, chromosomes, 
proteins, or metabolites, that detects genotypes, mutations, or chromosomal changes.” S. 306 
§ 201(7)(A). An individual’s family member is defined as “(A) the spouse of the individual; (B) 
a dependent child of the individual, including a child who is born to or placed for adoption with 
the individual; and (C) all other individuals related by blood to the individual or the spouse or 
child described in subparagraph (A) or (B).” Id. § 201(3).  
 67. See Stolberg, supra note 62, at A12; see also GINA of 2005, S. 306 §§  101–06. The 
health insurance requirements will apply to employer-sponsored group health plans, health 
insurance issuers in both group and individual markets, Medigap insurance, and non-federal 
governmental plans at the state and local levels. See America’s Health Insurance Plans, 
Summary of S. 1053, http://www.aahp.org/DocTemplate.cfm?Section=Genetics&template=/ 
ContentManagement/ContentDisplay.cfm&ContentID=12753 (last visited Aug. 16, 2006).  
 68. GINA of 2005, S. 306 § 202(b)(5) (“It shall be an unlawful employment practice for 
an employer to request, require, or purchase genetic information with respect to an employee or 
a family member of the employee . . . except . . . where the information involved is to be used 
for genetic monitoring of the biological effects of toxic substances in the workplace.”). 
Restrictions on this exception include the following requirements: the employer’s written notice 
of the monitoring to the employee; the employee’s written informed consent; informing the 
employee of the individual monitoring results; employer compliance with any federal 
monitoring regulations; and the employer receiving the monitoring results in a manner that does 
not disclose the identity of specific employees. Id. § 202(b)(5)(A)–(E).  
 69. See Stolberg, supra note 62, at A12. 
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discrimination resulting from the use of genetic information.70 This 
eliminates any exceptions to the use of genetic material for 
employers.71 If passed, a provision in GINA allows for a commission 
review of the Act and any relevant scientific discoveries in six 
years;72 this sunset provision makes a permanent ban on the use of 
genetic information uncertain.73 
Legal action under GINA is limited because it relies on the 
EEOC’s enforcement mechanisms.74 First, an individual must file a 
complaint against his or her employer with the EEOC, which will 
then determine if there is cause to believe that a GINA violation has 
occurred.75 At that point, the individual can bring a discrimination 
claim in state or federal court.76 In addition, GINA permits civil 
claims against employers but not against health insurers, and caps 
damages available against employers.77 
The bipartisan bill is described as “civil rights legislation,”78 and 
is hoped to “encourage millions of Americans to have genetic testing 
 
 70. GINA of 2005, S. 306 § 202; see also BISER, supra note 5, at 12. “[T]he employer 
bears the burden of proving a legitimate, nondiscriminatory basis for the employment action.” 
Harold P. Coxson, Newest Discrimination Law Covers the Broadest Possible Category of Your 
Workers, 1 No. 3 FED. EMP. L. INSIDER 1, 1 (Nov. 2003).  
 71. See BISER, supra note 5, at 12. “Instead of merely prohibiting ‘unfair’ discrimination, 
the act comprehensively prohibits the use of genetic information in employment decision-
making; there are no exceptions that would allow employers to use genetic information even if 
a condition poses a significant risk of a disabling condition.” Id. 
 72. GINA of 2005, S. 306 § 208(b); see also BISER, supra note 5, at 12 (“[I]t is possible 
that, as relevant tests are developed, [GINA] will be changed.”). 
 73. See GINA of 2005, S. 306 § 208(b). Critics approve of this “sunset provision,” 
believing that “there may come a day when Congress and the scientific community will want 
employers to collect and act on genetic information.” Coxson, supra note 70, at 1.  
 74. See BISER, supra note 5, at 12. Earlier versions of GINA permitted employee lawsuits 
to be filed directly in federal court. See Coxson, supra note 70, at 1. 
 75. See BISER, supra note 5, at 12.  
 76. See id.  
 77. See id. Harold Coxson reported: 
Although remedies would include full ‘make-whole’ relief, including reinstatement 
with back pay and front pay, damages would be capped at $300,000 (the same as Title 
VII of the Civil Rights Act of 1964, the ADA, and other federal employment 
discrimination laws). Earlier versions of the legislation . . . provided for unlimited 
punitive and compensatory damages. 
Coxson, supra note 70, at 1. 
 78. See Stolberg, supra note 62, at A12 (quoting Sen. Judd Gregg, Republican, N.H.). 
GINA is “for ‘a world where the secrets of human life have been plotted out and sheep have 
been cloned.’” Id. 
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done without fear of discrimination” by their employers or insurance 
companies.79 In addition, supporters anticipate that GINA will 
encourage participation in genetic research.80 The Senate report 
accompanying GINA states that the steps proposed by this legislation 
are “essential to fulfilling the promise of the human genome 
project.”81 The chief sponsor of the bill, Senator Olympia J. Snowe,82 
stated that “[t]he American people . . . cannot have access to the 
quality of care and the advancement of medical and scientific 
discoveries if they are subjected and held hostage to the fears of 
discrimination by their employers and by insurers.”83 
Opponents of GINA include health insurers and business groups, 
who deny the existence of discrimination and believe the legislation 
is unnecessary.84 These critics argue that GINA poses many 
problems, including the possibility of frivolous lawsuits,85 overbroad 
 
 79. See id. “With the genome mapping, researchers have developed tests for 
vulnerabilities to genetic disorders like cancer and diabetes . . . studies ha[ve] shown that up to 
one in three Americans eligible for the tests did not take them because they feared they could 
jeopardize their health coverage or jobs.” Id. (quoting Dr. Francis S. Collins). 
 80. See Aaron Zitner, Senate Blocks Genetic Discrimination, L.A. TIMES, Oct. 15, 2003, 
at A16. Dr. Francis Collins, director of the Genome Institute at the National Institutes of Health, 
said that participation in genetics research is hindered by fear of genetic discrimination. “In two 
studies of breast cancer and one of colon cancer, one-third of the individuals who were 
qualified to participate ultimately declined after hearing that there was no federal law against 
such discrimination . . . .” Id. “‘If Congress fails to act, we may well squander the vast potential 
of this research to improve the nation’s health,’ Sen. Edward M. Kennedy of Massachusetts, the 
senior Democrat on the health committee, said in a written statement.” Id. 
 81. S. REP. NO. 108-122, at 2 (2003). 
 82. See Stolberg, supra note 62, at A12. Senator Snowe is a Republican from Maine. Id. 
Senator Snowe “said one patient’s problems prompted her to begin work on the bill in 1996. 
Breast cancer had struck nine women in the patient’s family. But, Ms. Snowe said, the patient’s 
daughter was afraid to have genetic screening for breast cancer.” Id.  
 83. See id. 
 84. One such group is the Genetic Information Nondiscrimination in Employment (GINE) 
Coalition, a business community group. See Coxson, supra note 70, at 1; see also Laura 
Meckler, Bill Banning Genetic Discrimination Advances, CONN. L. TRIB., June 2, 2003, at 4. 
“‘Federal nondiscrimination legislation has never been based on potential or theoretical 
discrimination, but, rather, on some appreciable history of actual discrimination,’ R. Bruce 
Josten of the U.S. Chamber of Commerce said in a letter to Gregg.” Id. Supporters respond with 
the question, “Why wait for the discrimination to advance that far, especially if it impedes 
scientific and medical breakthroughs?” Coxson, supra note 70, at 1. 
 85. “[T]he legislation will serve as the basis for future unwarranted, frivolous lawsuits, 
which will be costly . . . to defend, challenging any adverse employment action as being based 
on . . . knowledge of the genetic information.” Coxson, supra note 70, at 1. Also, critics want 
GINA to preempt state genetic discrimination laws and other federal laws that might apply, “so 
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definitions,86 and the lack of a statute of limitations.87 The Bush 
administration has announced its support for GINA,88 and President 
Bush, while governor of Texas, enacted similar state legislation.89 
The United States House of Representatives is now considering the 
Genetic Information Nondiscrimination Act of 2005.90 
IV. THE LAWSUIT BETWEEN THE EEOC AND BURLINGTON 
NORTHERN & SANTA FE RAILWAY 
No case of genetic discrimination has been decided by a United 
States federal or state court.91 However, in 2001, the EEOC brought 
 
that employers aren’t faced with defending multiple charges and that the employee alleging 
genetic information discrimination should be required to make an ‘election of remedies.’” Id.  
 86. Critics believe that GINA’s scope should be limited to genetic testing only, and should 
not include things such as family history. Id. In addition, critics want a narrower definition of 
family member, which now includes anyone related by blood and adopted children, to include 
only the immediate family. Id. 
 87. “There’s no statute of limitations or legal defense based on the time elapsed from 
when the employer first learns about the genetic information and the unfavorable employment 
action.” Id.  
 88. See Stolberg, supra note 62, at A12. 
 89. See Coxson, supra note 70, at 1. President Bush views GINA as an extension of 
disability workplace protections such as the ADA, which was signed by his father, President 
George H.W. Bush. Id. In addition, the Bush Administration has stated that it: 
wants to work with Congress to ensure that individuals can be certain that they are 
protected against the improper use of genetic information. Unwarranted use of genetic 
information, and the fear of potential discrimination, threatens both society’s ability to 
use new genetic technologies to improve human health and the ability to conduct the 
very research needed to understand, treat, and prevent diseases. 
Id.  
 90. See National Human Genome Research Institute, Summary of S. 1053, 
http://www.genome.gov/11508845 (last visited Aug. 16, 2006). “Medical research advocates 
said the measure, if it became law, would speed the arrival of ‘personalized medicine,’ in which 
patients’ genes are studied to learn what diseases they are most vulnerable to and which 
treatments best suit them.” Zitner, supra note 80, at 30. However, Republican leadership has 
kept GINA and other genetic nondiscrimination bills introduced by House members tied up in 
committee. See Editorial, Genetic Privacy: House Ought to Follow the Senate’s Lead in 
Outlawing DNA Discrimination, BUFFALO NEWS, Oct. 25, 2003, at B4. 
 91. See Roche, supra note 13, at 271–72. For insight into how courts may handle genetic 
discrimination cases, see Chevron U.S.A., Inc. v. Echazabal, 536 U.S. 73, 86 (2002) 
(concluding that an employer may refuse to employ a disabled person under the ADA if 
employment would endanger his or her health); Bragdon v. Abbott, 524 U.S. 624, 641 (1998) 
(holding that HIV is a disability under the ADA despite the infection not progressing to the 
symptomatic phase, because HIV substantially limits the ability to reproduce, which is a major 
life activity); Norman-Bloodsaw v. Lawrence Berkeley Lab., 135 F.3d 1260, 1269–70, 1274 
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the first lawsuit alleging genetic discrimination against Burlington 
Northern & Santa Fe Railway (BNSF).92  
In 2001, BNSF, a company employing about 36,000 workers,93 
received approximately 125 disability claims from its employees for 
work-related injuries leading to carpal tunnel syndrome.94 BNSF 
requested certain employees alleging work-related carpal tunnel to 
submit to a medical examination, one part of which was a diagnostic 
blood test for a genetic marker believed to be associated with the 
development of the syndrome.95 The genetic marker was specifically 
for Hereditary Neuropathy with Liability to Pressure Palsies (HNPP), 
which is believed to be often accompanied by carpal tunnel 
syndrome.96 
The EEOC filed a court action alleging genetic discrimination 
against BNSF in February, 2001, in the U.S. District Court for the 
Northern District of Iowa.97 The EEOC sought a preliminary 
injunction against BNSF under the ADA to prohibit the genetic 
testing of the employees who filed disability claims for carpal tunnel 
syndrome.98 In addition, the EEOC sought to prevent disciplinary 
 
(9th Cir. 1998) (holding that blood tests did not violate the ADA, but that their secretive nature 
violated federal and state guarantees of privacy and unfairly discriminated against African-
Americans and women under Title VII); Laws v. Pact, Inc., 2000 WL 777926, at *3 (N.D. Ill. 
2000) (holding that a woman in the early stages of Huntington’s Disease was not discriminated 
against at the time of her termination because she was not substantially impaired in a major life 
activity).  
 92. EEOC v. Burlington N. Santa Fe Ry. Co., Civ. No. 01-4013 MWB (N.D. Iowa Apr. 
18, 2001) (granting preliminary settlement of injunctive claims); see also EEOC v. Burlington 
& Santa Fe Ry. Co., No. 02-C-0456, 2002 WL 32155386 (E.D. Wis. 2002) (granting monetary 
settlement).  
 93. BNSF, BNSF Facts, http://www.bnsf.com/media/bnsffacts.html (last visited Aug. 16, 
2006). 
 94. See Roche, supra note 13, at 276. Carpal tunnel syndrome, the entrapment of the 
nerve at the wrist, usually occurs with excessive use of the wrist. See HARRISON’S PRINCIPLES 
OF INTERNAL MEDICINE 2501–02 (Dennis L. Kasper et al. eds., 16th ed. 2005). The main 
symptoms are nocturnal itching and tingling of the thumb, index, and middle fingers. Id. With 
worsening, numbness occurs in the area. Id. Carpal tunnel syndrome is believed to be caused or 
worsened by repetitive hand or wrist motions, similar to those required to operate railway 
machinery or pound railway spikes. See Roche, supra note 13, at 276. 
 95. See Burlington Northern, 2002 WL 32155386.  
 96. See Stephen Fink, EEOC v. BNSF: The Risks and Rewards of Genetic 
Exceptionalism, 42 WASHBURN L.J. 525, 527 (2003). 
 97. See EEOC Feb. Press Release, supra note 40. 
 98. See id. BNSF had a policy that required any employee who filed a disability claim for 
carpal tunnel syndrome to submit blood samples for a genetic DNA test. Id. The genetic test 
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action against or termination of any employee who refused the 
genetic test.99 
The EEOC alleged that BNSF employees were neither informed 
of or asked to consent to the genetic test.100 The EEOC also alleged 
that at least one individual refused to provide a blood sample for the 
test, and was “threatened with imminent discharge if he fail[ed] to 
submit the sample.”101 
The EEOC and BNSF reached a settlement agreement out of court 
in April, 2001, in the form of an agreed order.102 BNSF admitted that 
it tested certain employees who alleged carpal tunnel syndrome for 
the genetic marker.103 The order specified that BNSF shall not 
“directly or indirectly require its employees to submit blood for 
genetic tests”; “analyze any blood previously obtained”; “evaluate, 
analyze or consider any gene test analysis previously performed on 
any of its employees”; or “retaliate or threaten to take any adverse 
action against any person who opposed the genetic testing or who 
participated in EEOC’s proceedings.”104 However, because the 
parties reached a settlement, the court had no occasion to rule on the 
parties’ arguments under the ADA,105 giving no further guidance as 
to how genetic privacy and discrimination cases will be decided and 
 
was designed to reveal a chromosome seventeen deletion, which some claim predicts forms of 
carpal tunnel syndrome. Id.  
 99. See id. The EEOC determined that “employees would suffer irreparable injury through 
the invasion of their most intimate privacy rights if the practice of testing is not ended.” Id. 
(quoting Chester V. Bailey, Director of the EEOC’s Milwaukee District Office). 
 100. See id. 
 101. Id. The employee suspected that the blood samples requested would be used for 
genetic testing. Id.  
 102. See Press Release, EEOC, EEOC Settles ADA Suit Against BNSF for Genetic Bias 
(Apr. 18, 2001), available at http://www.eeoc.gov/press/4-18-01.html [hereinafter EEOC Apr. 
Press Release]. 
 103. See id.; see also Finkelstein, supra note 21, at 5. BNSF had “the clear intent of trying 
to figure out a way to let employees go if they might be at some risk of collecting workman’s 
comp.” Id. (quoting Dr. Francis Collins). 
 104. EEOC Apr. Press Release, supra note 102. In addition, the order provided that “BNSF 
shall preserve all evidence relevant to its genetic testing until several charges of discrimination 
filed with EEOC against the company are resolved,” and that “EEOC may seek compensatory 
and punitive damages up to $300,000 per individual (the statutory cap) for a class of claimants 
ranging from 20 to 30 BNSF workers who were either subjected to genetic testing or retaliated 
against for failing to submit to such tests.” Id.  
 105. See LAURIE, supra note 7, at 160. 
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leaving unanswered “the question of the legality of genetic 
susceptibility monitoring programs.”106 
After agreeing to the order halting the genetic testing, BNSF and 
the EEOC mediated a monetary settlement of $2.2 million in May, 
2002.107 BNSF denied engaging in unlawful testing or workplace 
discrimination in violation of the ADA,108 but agreed to settle the 
charges with the EEOC through voluntary mediation.109 BNSF 
agreed to “not use genetic tests in required medical examinations of 
its employees . . . provide enhanced ADA training to its medical and 
claims personnel . . . and . . . have senior management review of all 
significant medical policies and practices.”110 
V. APPLYING GINA TO THE BURLINGTON NORTHERN & SANTA FE 
RAILWAY CASE 
If another case of genetic discrimination similar to BNSF were to 
occur, would GINA be of any value? Would the employee have any 
additional protections, or would the employer be permitted to test? 
How is susceptibility testing protected under GINA? Would BNSF be 
able to allege that its testing is different and not used in a 
discriminatory manner? These are just a few of the many questions 
raised by GINA’s possible enactment. 
Applying GINA’s provisions to the facts of the BNSF case, it is 
likely that the outcome would not be substantially different from the 
settlement terms. BNSF requested certain employees who alleged 
work-related carpal tunnel syndrome to submit to a medical 
examination, one part of which was a diagnostic blood test for a 
genetic marker believed to be associated with the development of the 
 
 106. BISER, supra note 5, at 9. 
 107. EEOC v. Burlington N. & Santa Fe Ry. Co., No. 02-C-0456, 2002 WL 32155386 
(E.D. Wis. 2002); see Press Release, EEOC, EEOC and BNSF Settle Genetic Testing Case 
Under Americans with Disabilities Act (May 8, 2002), available at http://www.eeoc.gov/ 
press/5-8-02.html [hereinafter EEOC May Press Release]. 
 108. See EEOC May Press Release, supra note 107. EEOC Commissioner Paul Steven 
Miller noted that, “[w]hile the EEOC did not find that BNSF had used genetic tests to screen 
out employees, employers should be aware of the EEOC’s position that the mere gathering of 
an employee’s DNA may constitute a violation of the ADA.” Id. 
 109. See id.  
 110. Id.; see also Joanne L. Hustead and Janlori Goldman, Genetics and Privacy, 28 AM. 
J.L. & MED. 285 n.55 (2002). 
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syndrome.111 Under GINA, although there are several provisions that 
may allow such genetic testing, BNSF did not comply with the 
imposed requirements.  
To require a genetic test in compliance with GINA, BNSF would 
have to offer the medical services as part of a bona fide wellness 
program,112 with prior informed written consent by the employee,113 
and it would have to disclose the results only to the employee and the 
physician.114 BNSF’s actions did not conform to these standards. 
BNSF employees were neither informed of nor asked to consent to 
the genetic test, violating GINA.115 BNSF’s threat to terminate an 
employee who refused to provide a blood sample for the genetic test 
is an additional GINA violation.116 Further, it would be difficult for 
BNSF to assert that the genetic test was part of a bona fide wellness 
program because only those employees who had previously 
submitted a disability claim for carpal tunnel were required to 
undergo the genetic test.117 
Another possible route by which to allow the genetic test requires 
that BNSF show that the test was intended to monitor workplace 
conditions.118 However, the GINA provision under which this might 
 
 111. See supra notes 94–95 and accompanying text.  
 112. GINA of 2005, S. 306, 109th Cong. § 202(b)(2)(A) (2005) (allowing an exception for 
genetic testing “[w]here health or genetic services are offered by the employer, including such 
services offered as part of a bona fide wellness program”). The Senate Report on GINA 
describes this exception as necessary 
to achieve the bill’s stated goal of encouraging employees to take advantage of genetic 
technologies and opportunities to improve human health without fear of discrimination 
by their employer. . . . Participation in the program must be voluntary and confidential, 
and safeguards must be in place to ensure that the sponsoring employer . . . does not 
have access to individually identifiable health information. . . .  
S. REP. NO. 108-122, at 27 (2003).  
 113. GINA of 2005, S. 306 § 202(b)(2)(B) (allowing an exception “where the employee 
provides prior, knowing, voluntary, and written authorization”). 
 114. Id. § 202(b)(2)(C) (allowing an exception “where only the employee (or family 
member if the family member is receiving genetic services) and the licensed health care 
professional or board certified genetic counselor involved in providing such services receive 
individually identifiable information concerning the results of such services”). 
 115. See supra notes 99, 110 and accompanying text. 
 116. See supra notes 100, 110 and accompanying text. 
 117. See supra notes 94, 111 and accompanying text. 
 118. GINA of 2005, S. 306 § 202(b)(5)(B)(ii) (allowing an exception “where the 
information involved is to be used for genetic monitoring of the biological effects of toxic 
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occur specifically refers to toxic substances.119 It would be difficult, 
if not impossible, to connect a toxic substance with carpal tunnel 
syndrome,120 especially when the condition is believed to result from 
operating railway machinery or pounding railway spikes.121 
Based on the proposed GINA legislation, the BNSF employees 
would have a plausible case of genetic discrimination. Although 
BNSF admitted that it tested certain employees alleging carpal tunnel 
syndrome for a genetic marker,122 it denied any wrongdoing, 
unlawful testing, or workplace discrimination.123 However, provided 
that the EEOC could prove its alleged facts, BNSF would nonetheless 
be liable to those employees under GINA for genetic discrimination 
in employment practices.  
VI. WILL GINA REALLY PROTECT? SHOULD IT BE ENACTED? 
Despite the limited known instances of genetic discrimination, the 
public is concerned. This fear of genetic discrimination affects 
participation in genetic research trials and willingness to undergo 
genetic tests, because of the risk of discriminatory action by an 
employer or insurer.  
The 2003 Senate report on GINA provides many reasons why 
federal legislation prohibiting genetic discrimination is necessary. 
Legislators believe it is important to prevent “[e]nabling employers, 
health insurers and others to base decisions about individuals on the 
characteristics that are assumed to be their genetic destiny,” because 
it “would be an undesirable outcome of our national investment in 
genetic research, and may significantly diminish the benefits that this 
research offers.”124 
 
substances in the workplace, but only if . . . the genetic monitoring is required by Federal or 
State law”). 
 119. See supra notes 98, 108 and accompanying text.  
 120. See supra note 91 and accompanying text. For additional information on carpal tunnel 
syndrome, see National Institute of Neurological Disorders and Stroke, Carpal Tunnel 
Syndrome Information Page, http://www.ninds.nih.gov/disorders/carpal_tunnel/carpal_tunnel. 
htm (last visited Aug. 16, 2006).  
 121. See supra note 91 and accompanying text.  
 122. See supra note 100 and accompanying text. 
 123. See supra note 105 and accompanying text.  
 124. S. REP. NO. 108-122, at 6 (2003).  
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GINA should be enacted because it “provides the broadest 
employment discrimination coverage and workplace protections of 
any discrimination law in the nation’s history.”125 The legislation 
would assure the public that employers and insurers cannot 
discriminate against individuals based on their genetic make-up. 
While some disagree with the need for federal legislation because of 
the few documented cases of genetic discrimination, the correct 
approach is a preemptive one. Although genetic testing is not 
currently widespread, it is much easier to address the problem now, 
rather than waiting until it is standard practice for insurance 
companies and employers to have access to genetic information.126 
By enacting GINA, Congress will protect individuals from genetic 
discrimination and make it more likely that they will participate in 
genetic research and benefit from genetic tests and technology.127  
CONCLUSION 
The idea of genetic privacy is one of current concern for the 
American public. Proposed federal legislation, GINA, will afford all 
citizens the right to genetic privacy as applied to employment and 
insurance. Although scholars debate whether genetic privacy and 
genetic discrimination are pressing concerns requiring federal 
legislation, many argue that the best way to further development in 
genetic research and to secure citizen cooperation in clinical research 
trials is to legislate, thereby alleviating the public’s fear of genetic 
discrimination. 
 
 125. Coxson, supra note 70, at 1.  
 126. Wal-Mart recently circulated a memo discussing ways to cut the costs of employee 
benefits. Steven Greenhouse & Michael Barbaro, Wal-Mart Memo Suggests Ways to Cut 
Employee Benefit Costs, N.Y. TIMES, Oct. 26, 2005, at C1. The main tone of the memo, 
discouraging unhealthy workers and job applicants and focusing particularly on obesity, could 
be seen as an attempt at a form of genetic discrimination by the company. “The memo proposed 
incorporating physical activity in all jobs and promoting health savings accounts [which] are 
financed with pretax dollars and allow workers to divert their contributions into retirement 
savings if they are not all spent on health care . . . these accounts will be more attractive to 
younger, healthier workers.” Id. 
 127. “It is only fitting that in 2003, a year filled with historic DNA milestones, the U.S. 
Congress and the president move forward to give a present to the American people: enactment 
of a nondiscrimination law protecting all of us.” Francis Collins & James D. Watson, Editorial, 
Genetic Discrimination: Time to Act, 302 SCIENCE 745 (2003).  
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Federal legislation should be enacted as soon as possible, although 
it appears that GINA is on the back burner in the United States House 
of Representatives. The United States Senate, as demonstrated by its 
unanimous passage of both the 2003 and 2005 versions of GINA, is 
eager to enact federal legislation that protects American citizens from 
genetic discrimination in employment and insurance. The House of 
Representatives should follow the lead of the Senate and pass GINA 
as well. The quicker the House acts, the more protection the 
American public will have, and, as a result, the greater the chance 
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